A woman from Michigan, who lost her ability to speak due to a rare neurodegenerative disease, has been able to communicate in real time with her grandchildren using a groundbreaking implant that translates her silent thoughts into spoken words and text. This achievement marks a major milestone in the development of brain-computer interfaces. The woman, who suffers from primary lateral sclerosis (PLS), a condition that progressively damages the nerve cells responsible for controlling speech, swallowing, and movement, has retained a faint voice that is no longer understandable to others. The implant, called Connexus, developed by the company Paradromics, allows her to express herself freely for the first time in years. In June 2026, a team of surgeons from the University of Michigan Health performed a procedure in which over 400 microelectrodes were implanted into her brain's cortex. These electrodes are connected to a transmitter-receiver device placed in her chest, which communicates wirelessly with an external computer. The system uses artificial intelligence to interpret raw neural signals, converting them into text and synthetic speech. This technology enabled the woman to engage in spontaneous conversations, answer open-ended questions, and even make phone calls to her grandchildren. The implant is designed to detect three distinct types of brain activity related to communication—when she tries to speak, when she imagines speaking, and when she listens to others. One of the notable features of the Connexus implant is its ability to represent words and sounds in the brain, regardless of whether the person is attempting to speak, imagining speech, or listening. However, the system's ability to decode imagined speech is still somewhat imprecise, with Vikash Gilja, the scientific director at Paradromics, describing it as "as if it enters and exits the focus." He notes that the clarity of the decoded speech is expected to improve with continued use and training. Edward Chang, a leading neurosurgeon at the University of California, San Francisco, praised the system for being fully autonomous and wireless, a significant improvement over earlier systems that required a physical connection to the skull, increasing the risk of infection and limiting mobility. While the results are promising, they come from a company press release and have not yet been peer-reviewed or published in a scientific journal. The Connect-One clinical trial, which the U.S. Food and Drug Administration (FDA) has approved, is currently in its early feasibility phase, with only one patient implanted so far out of ten planned. Before the implant can be commercialized, further trials are needed to confirm the long-term durability of the intracortical electrodes and to ensure the technology's safety and effectiveness over time.